Global Sales Revenue and Competitive Outlook of ADC Drugs in 2021

Author: leaves

In February 2022, Johnson & Johnson and Eli Lilly entered into an antibody-drug conjugate (ADC) cooperation with Mersana and ImmunoGen, respectively.
Both parties will invest over $1 billion to enter the ADC track
.

The addition of these two giants has also added a new changing force to the ADC drug market that was already attracting attention

The overall market size of global ADC drugs will exceed US$5 billion in 2021.
Although this figure does not seem to be as good as the annual sales of a super blockbuster product, it does not seem to match the popularity of the ADC field, but you must know that ADC Most of the drugs are still clinical late-line therapies, and some innovative first-of-its-kind ADC drugs have just been approved, and the market is still cultivating, and their performance in the first two or three years is still good
.

This article mainly analyzes the market structure of ADC drugs for your reference

Global sales of ADC drugs in 2021 (billion US dollars)

Note: 1) The data comes from the company's financial report; 2) The Enhertu data is disclosed by AstraZeneca, representing markets outside Japan (AstraZeneca/Daichi Sankyo is jointly responsible), excluding sales revenue in the Japanese market (Daichi Sankyo is independently responsible for it) , the sales revenue in the first three quarters of fiscal 2021 is about 60 million US dollars)

The pattern of old products has been determined, and the potential of new products is emerging

The pattern of old products has been determined, and the potential of new products is emerging

Kadcyla (trastuzumab) and Adcetris (velbutuximab) are mature ADC drugs with relatively early market time, occupying an absolute dominant share in the current ADC market
.

As the first ADC drug in the field of solid tumors, Kadcyla ranked first with sales performance of nearly 2 billion Swiss francs, an increase of 16% year-on-year, and double-digit growth showed good growth potential

The combined sales of Adcetris (Velbutuximab) jointly developed by Seagen/Takeda also exceeded US$1.
3 billion, second only to the market size of Kadcyla
.

Velbutuximab is currently the first-line standard therapy for CD30-positive Hodgkin lymphoma and peripheral T-cell lymphoma in the United States, and the statistically significant improvement in OS also makes it a clinically basic treatment

AstraZeneca/Daiichi Sankyo Enhertu (DS-8201, HER2 ADC) and Gilead’s Trodelvy (goxatuzumab, TROP2 ADC) show huge growth potential
.

Enhertu was approved at the end of 2019, and 2020 is the first full financial year.
In markets other than Japan, Enhertu's global revenue in 2021 is US$426 million (US$202 million in 2020)
.

In 2021, Enhertu disclosed positive data in a head-to-head clinical phase III study in Her2-positive breast cancer, which significantly improved patient OS compared to Kadcyla
.

The supplementary application of Enhertu for the second-line treatment of Her2-positive breast cancer has been granted priority review by the FDA, and it is expected to be approved for marketing in the first half of 2022.

In addition, the clinical study data (DESTINY-Breast04) of Enhertu in the third-line treatment of breast cancer patients with low expression of Her2 will also be announced and submitted for marketing application in 2022
.

Enhertu is also conducting research in neoadjuvant therapy for HER2+ breast cancer

In 2021, goxatuzumab will achieve sales revenue of US$380 million in its first full year, which is the best performing ADC drug in the market in recent years
.

In April 2021, goxatuzumab was fully approved by the FDA for the treatment of triple-negative breast cancer, and at the same time, it ushered in the expansion of urothelial cancer indications, which led to a continuous increase in sales performance

In the first half of 2022, the clinical phase III data of goxatuzumab in HR+/HER2- metastatic breast cancer will be announced, and a marketing application will be submitted in the second half of the year
.

The first-mover advantage of goxatuzumab will keep it in the market in the next few years, and similar products (such as datopotamab deruxtecan) will not submit a marketing application for the same indication in the short term

GlaxoSmithKline's Blenrep (belantamab mafodotin) is currently indicated for the end-line treatment of multiple myeloma (5th line and above), and its clinical use is very late.
It will also generate $122 million in revenue in 2021.
If the treatment can be realized The drug line level is moved forward, and the market sales volume is also expected to increase significantly
.

ADC investment and financing transactions are hot, cooperation and authorization are active

ADC investment and financing transactions are hot, cooperation and authorization are active

In addition to seeing confidence in the future growth of ADC products in sales performance, financing and transaction cooperation in this field will also continue to be hot in 2021
.
The 1 billion RMB Series C financing of Duoxi Bio has become the domestic “top card”, and the 2.
6 billion USD transaction of Rongchang Bio has created a new record of China’s innovative drug license out
.

According to the data of Medicine Cube, more than 40 financing events (including IPOs) were disclosed in the ADC drug field in 2021, and more than 60% of the financing occurred in China, and the popularity continued to heat up
.
New drug conjugates such as ISAC, PDC, VDC, ACC, and AnDC will also trigger financing events in 2021
.

Investment and financing transactions are hot, and cooperation authorization is also in various forms
.
In addition to the cooperation authorization and introduction of pure products, cooperation involving ADC drug technology is also increasing
.
Domestic and foreign companies such as Innovent Bio, Mayac, Pufang Bio, MacroGenics, Mersana and Mersana have reached hundreds of millions of dollars in cooperation or expanded cooperation with Synaffix to help companies deploy ADC drugs
.
In addition, Emergence Therapeutics played a new trick with license in, and built its own ADC products by introducing antibodies, Linkers and payloads respectively
.

The addition of Johnson & Johnson and Eli Lilly makes the field even more exciting in 2022
.
Looking back to 2021, the studies of SBT6050 and BDC-1001 were bleak but did not make the immunostimulatory conjugated drug fall into the dust, and SBT6290 has already started a new clinical study
.
Looking forward to 2022, there is reason to believe that financing and transaction cooperation in the ADC field will continue, and we look forward to more excellent clinical progress, especially the positive data of new conjugated drugs (such as masked peptides and loaded prodrugs)
.